Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- JPWA President Expresses Opposition to Market Price Survey in Conjunction with Sales Tax Hike, Calls for “Simplified Survey” If Necessary
January 6, 2016
- JGA Deeply Sorry for Making Baseless Demand on FY2016 Drug Pricing Reform
January 5, 2016
- Re-Pricing of Huge Seller Drugs “Extremely Unreasonable”: FPMAJ
January 5, 2016
- FPMAJ Chief Says It’s Time for Social Security Overhaul, Sub-Optimization Has Reached Limit
January 5, 2016
- Special Re-Pricing of Huge-Seller Drugs “Unacceptable,” JPMA Says on FY2016 Reform
December 25, 2015
- JPWA to Establish Taskforce to Discuss Measures for Distribution Problems Cited in Ryukaikon’s New Proposal
December 24, 2015
- JPMA Reprimands Novartis over Side Effect Reporting Violation
December 18, 2015
- JPMA to Watch Regulators’ Moves to Decide Its Action on Kaketsuken
December 18, 2015
- JPMA Says Re-Pricing of Huge-Seller Drugs Unreasonable, Preparing Statement
December 18, 2015
- Lilly’s Jonsson to Become Japan Chief of PhRMA
December 18, 2015
- PhRMA Sounds Alarm on “Huge Seller” Re-Pricing, Possible Decline in Japan Investment
December 14, 2015
- JGA Chief Opposes 50% First Generic Pricing for Non-Oral Drugs with Adoair, Symbicort Generics in Mind
December 11, 2015
- JPMA Sets to Respond Harshly to Kaketsuken Cover-Up: Chief
December 8, 2015
- JPMA Requests on Price Revisions, Tax Seem to Have Sunk in for Politicians: Exec
November 20, 2015
- 6 Insurers Tender Request for FY2016 Reform, Say Healthcare Costs Must Be Cut with HTA, Generics
November 19, 2015
- Industry Wants OTC Tax Break and No Annual Price Cuts, Groups Tell LDP
November 19, 2015
- Pharma Leaders Rev Up Lobbying Campaigns ahead of Year-End Budget, Tax Debates
November 18, 2015
- FPMAJ Gives Up on Crafting Rules for Disclosing Joint Generic Developers
October 27, 2015
- Reflect Industry Opinions in Pilot Introduction of Cost-Effective Assessments: JPMA
October 27, 2015
- JPMA Says Its Demands Generally Accepted in TPP, No Impact Expected on Japan Market
October 23, 2015
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…